Glycopyrrolate Oral Solution Dosing (1 mg/5 mL)
For children aged 3-16 years with chronic severe drooling, start glycopyrrolate oral solution at 0.02 mg/kg three times daily and titrate upward in 0.02 mg/kg increments every 5-7 days based on response and tolerability, up to a maximum of 0.1 mg/kg three times daily (not exceeding 1.5-3 mg per dose based on weight). 1
Pediatric Dosing Algorithm
Initial Dosing
- Starting dose: 0.02 mg/kg orally three times daily 1
- Timing: Administer at least 1 hour before or 2 hours after meals (high-fat meals reduce bioavailability by 78%) 1
- Age restriction: FDA-approved for ages 3-16 years; safety not established under 3 years 1
Titration Schedule
- Increment: Increase by 0.02 mg/kg every 5-7 days 1
- Assessment: Before each dose increase, review tolerability with caregivers, particularly monitoring for constipation within 4-5 days 1
- Maximum dose: 0.1 mg/kg three times daily, not exceeding 1.5-3 mg per dose depending on weight 1
Weight-Based Dosing Table (from FDA label)
For a child weighing 18-22 kg (39-49 lbs):
- Dose Level 1: 0.4 mg (2 mL) three times daily
- Dose Level 2: 0.8 mg (4 mL) three times daily
- Dose Level 3: 1.2 mg (6 mL) three times daily
- Dose Level 4: 1.6 mg (8 mL) three times daily
- Dose Level 5: 2.0 mg (10 mL) three times daily 1
For a child weighing ≥48 kg (≥105 lbs):
- Maximum per dose: 3.0 mg (15 mL) three times daily 1
Clinical Efficacy Evidence
The pivotal trial demonstrated 73.7% responder rate (≥3-point improvement on modified Teacher's Drooling Scale) versus 17.6% with placebo at 8 weeks, with improvements starting at 2 weeks 2. Mean improvement was 3.94 points versus 0.71 points for placebo (P<0.0001) 2.
Adult Dosing
For adults, no FDA-approved dosing exists for the oral solution formulation. The evidence base consists primarily of case reports using 1-4 mg daily in divided doses 3. One case report showed marked reduction in drooling with 3-4 mg daily (given as 1 mg tablets) 3. However, this is off-label use without established safety or efficacy data in adults.
Critical Safety Considerations
Common Adverse Events (requiring monitoring):
- Constipation (dose-limiting; assess within 4-5 days of initiation or dose increase) 1
- Dry mouth (most common) 1, 2
- Vomiting 1, 2
- Flushing and nasal congestion 1
Discontinuation Rate
20-36% discontinue due to adverse effects, primarily gastrointestinal issues and behavioral changes 4, 5, 6. In the most recent real-world study, 36% stopped treatment due to ADRs 6.
Contraindications (absolute):
- Glaucoma
- Paralytic ileus
- Myasthenia gravis
- Concurrent solid oral potassium chloride 1
Special Populations
- Renal impairment: Use with extreme caution; elimination is severely impaired (mean clearance reduced from 1.14 to 0.43 L/hr/kg) 1
- High ambient temperatures: Risk of heat prostration due to decreased sweating 1
Practical Administration Points
- Measuring device: Must use accurate measuring device (not household spoon) 1
- Meal timing: Critical to dose 1 hour before or 2 hours after meals 1
- Titration period: 4-week titration allows individualized dosing while monitoring anticholinergic effects 1
- Response assessment: Evaluate at 2 weeks (earliest improvement seen) and 8 weeks (full effect) 2
The dose range is surprisingly broad (0.01-0.82 mg/kg/day in one study), reflecting significant inter-individual variability in response and tolerance 5. This necessitates careful titration rather than fixed dosing.